Skip to main content

Table 3 Characteristics and FDG PET/CT scan findings in SSc patients without ILD (n = 14) and with ILD (n = 22)

From: 18F-FDG positron emission tomography scanning in systemic sclerosis-associated interstitial lung disease: a pilot study

  SSc patients without ILD (n = 14) SSc patients with ILD (n = 22) p value
Potential confusion factors
 Sex, female, no. (%) 11 (78.6) 9 (40.9) 0.027
 Age, years, mean ± SD 54.6 ± 14.3 61.3 ± 10.6 0.12
 BMI, kg/m2, mean ± SD 25.6 ± 5.8 25.1 ± 6.0 0.80
 Glycemia, g/L, mean ± SD 1.1 ± 0.3 1.0 ± 0.1 0.35
 Injection-perfusion duration, minutes, mean ± SD 70.3 ± 11.9 75.6 ± 11.9 0.20
Disease characteristics
 Cutaneous subset, limited, no. (%) 8 (57.1) 11 (50.0) 0.68
 Disease duration, no. (%)    0.11
  < 2 years 8 (57.1) 6 (27.3)  
  2–4 years 1 (7.1) 7 (31.8)
  > 4 years 5 (35.7) 9 (40.9)
 Antibody status, no. (%)
  Anti-nuclear 13 (92.9) 21 (95.5) NA
  Anti-centromere 7 (50.0) 5 (22.7) 0.15
  Anti-topoisomerase I 1 (7.1) 9 (40.9) 0.054
  Anti-RNA polymerase III 1 (7.1) 3 (13.6) NA
Organ involvement, no. (%)
 Lung
  Current %FVC, mean ± SD 100 ± 10 80 ± 20 0.015
  Current %DLCO, mean ± SD 70 ± 20 50 ± 20 0.002
 Osteoarticular 7 (58.3) 7 (35.0) 0.20
 Muscle 3 (27.3) 3 (23.1) NA
 Current mRSS, mean ± SD 13.6 ± 13.1 13.9 ± 11.5 0.96
 Gastrointestinal tract 9 (64.3) 15 (68.2) 1.00
 Pulmonary hypertension 3 (21.4) 5 (22.7) NA
 Calcinosis 2 (14.3) 2 (10.5) NA
 Telangiectasia 11 (78.6) 11 (52.4) 0.12
 Ulcer digital 3 (21.4) 7 (35.0) 0.47
 Heart 1 (7.1) 5 (22.7) NA
Current treatments, no. (%)
 Steroids 3 (21.4) 10 (45.5) 0.14
 Immunosuppressive drugs 3 (21.4) 10 (45.5) 0.14
18F-FDG PET/CT scan findings, no (%)
 Lung
  Abnormal interstitial pattern 1 (7.1) 14 (63.6) <.001
  hv/SUVmax, mean ± SD 1.4 ± 0.8 2.6 ± 0.9 <.001
  s/SUVmax, mean ± SD 9.8 ± 4.1 17.3 ± 6.0 <.001
  s/Intensities, median (IQR) 0.0 (0.0; 0.0) 8.0 (2.0; 12.0) <.001
 Lymph node
  Mediastinal, abnormal pattern 2 (14.3) 7 (31.8) 0.43
  Hilar, abnormal pattern 2 (14.3) 6 (27.3) 0.44
 Osteoarticular, abnormal pattern 0 (0.0) 1 (4.5) NA
 Muscle, abnormal pattern 1 (7.1) 2 (9.1) NA
 Skin, abnormal pattern 1 (7.1) 1 (4.5) NA
 Esophagus, abnormal pattern 9 (64.3) 17 (77.3) 1.0
  1. BMI body mass index, %FVC forced vital capacity (as % predicted values), %DLCO diffusing capacity for the lung of carbon monoxide (as % predicted values), hv/SUVmax highest value of the SUVmax among the 10 pulmonary SUVmax, IQR interquartile range, SD standard deviation, s/Intensities sum of the 10 pulmonary intensities, s/SUVmax sum of the 10 pulmonary SUVmax, NA not applicable. p value adjusted on BMI = 0.021; p value adjusted on BMI, <.001